New and emerging treatments for metabolic dysfunction-associated steatohepatitis
Metabolic dysfunction-associated steatohepatitis (MASH) is a leading etiology of chronic liver disease worldwide. In this review, Tincopa et al. highlight challenges and potential solutions in drug development for MASH. They cover current advances in pharmacotherapy for MASH, presenting promising data from several agents in the pipeline.